DR   cancercelllines; CVCL_LM95
DR   Millipore; SCC141
DR   Wikidata; Q54585282
RX   DOI=10.14800/ccm.134;
RX   DOI=10.4236/scd.2013.33024;
RX   PubMed=19160414;
RX   PubMed=23129384;
CC   Problematic cell line: Contaminated. Shown to be a RD derivative (personal communication of Millipore). Originally thought to be a MG-63 derivative.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00545.
CC   Population: Caucasian.
CC   Characteristics: Was thought to have cancer stem cell-like characteristics as it was thought to be produced by long term treatment of MG-63 with 3-aminobenzamide (3AB), an inhibitor of poly(ADP-ribose) polymerase.
CC   Doubling time: ~22 hours (PubMed=19160414).
CC   Selected for resistance to: ChEBI; CHEBI:64042; 3-aminobenzamide (3AB).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Discontinued: Millipore; SCC141; true.
CC   Derived from site: In situ; Pelvis, muscle; UBERON=UBERON_0001325.
ST   Source(s): Millipore=SCC141
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 13
ST   D16S539: 10,11
ST   D18S51: 13,18
ST   D21S11: 28,29
ST   D3S1358: 15,17
ST   D5S818: 11
ST   D7S820: 8,12
ST   D8S1179: 11,14,15
ST   FGA: 20,21
ST   Penta D: 11,13
ST   Penta E: 12
ST   TH01: 9.3
ST   TPOX: 9
ST   vWA: 18
DI   NCIt; C8971; Embryonal rhabdomyosarcoma
DI   ORDO; Orphanet_99757; Embryonal rhabdomyosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1649 ! RD
SX   Female
AG   7Y
CA   Cancer cell line
DT   Created: 15-11-17; Last updated: 02-05-24; Version: 15
RX   DOI=10.14800/ccm.134;
RA   Di Fiore R., Drago-Ferrante R., Marcatti M., Carlisi D., Tesoriere G.,
RA   Vento R.;
RT   "A short story of 3AB-OS cancer stem cells, a possible model for
RT   studying cancer stemness.";
RL   Cancer Cell Microenviron. 1:e134.1-e134.5(2014).
RX   DOI=10.4236/scd.2013.33024;
RA   Di Fiore R., Drago-Ferrante R., D'Anneo A., De Blasio A., Santulli A.,
RA   Messina C., Carlisi D., Tesoriere G., Vento R.;
RT   "Differentiation of human osteosarcoma 3AB-OS stem-like cells in
RT   derivatives of the three primary germ layers as a useful in vitro
RT   model to develop several purposes.";
RL   Stem Cell Discov. 3:188-201(2013).
RX   PubMed=19160414; DOI=10.1002/jcp.21667;
RA   Di Fiore R., Santulli A., Drago-Ferrante R., Giuliano M., De Blasio A.,
RA   Messina C., Pirozzi G., Tirino V., Tesoriere G., Vento R.;
RT   "Identification and expansion of human osteosarcoma-cancer-stem cells
RT   by long-term 3-aminobenzamide treatment.";
RL   J. Cell. Physiol. 219:301-313(2009).
RX   PubMed=23129384; DOI=10.1002/jcp.24272;
RA   Di Fiore R., Fanale D., Drago-Ferrante R., Chiaradonna F.,
RA   Giuliano M., De Blasio A., Amodeo V., Corsini L.R., Bazan V.,
RA   Tesoriere G., Vento R., Russo A.;
RT   "Genetic and molecular characterization of the human osteosarcoma
RT   3AB-OS cancer stem cell line: a possible model for studying
RT   osteosarcoma origin and stemness.";
RL   J. Cell. Physiol. 228:1189-1201(2013).